Weiwei Tan

8.9k total citations · 1 hit paper
59 papers, 1.9k citations indexed

About

Weiwei Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Weiwei Tan has authored 59 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Weiwei Tan's work include Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (16 papers) and HER2/EGFR in Cancer Research (9 papers). Weiwei Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (16 papers) and HER2/EGFR in Cancer Research (9 papers). Weiwei Tan collaborates with scholars based in United States, China and Italy. Weiwei Tan's co-authors include Keith D. Wilner, Zhongzhou Shen, Susumu Kobayashi, Shuchi S. Pandya, Wee-Lee Yeo, Daniel B. Costa, Benjamin Solomon, D. Ross Camidge, Sai‐Hong Ignatius Ou and Ravi Salgia and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Weiwei Tan

56 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

2011 474 citations Weiwei Tan, Keith D. Wilner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weiwei Tan United States	20	1.2k	1.0k	809	232	188	59	1.9k
Peter Stopfer Germany	28	1.4k 1.2×	1.5k 1.4×	878 1.1×	191 0.8×	154 0.8×	69	2.6k
Atsushi Horiike Japan	28	1.3k 1.1×	1.3k 1.3×	604 0.7×	391 1.7×	152 0.8×	107	2.1k
Monica Motwani United States	22	577 0.5×	1.2k 1.1×	895 1.1×	302 1.3×	371 2.0×	45	2.0k
Remy B. Verheijen Netherlands	18	794 0.7×	630 0.6×	542 0.7×	182 0.8×	102 0.5×	50	1.4k
G. Deplanque France	23	812 0.7×	1.3k 1.2×	633 0.8×	542 2.3×	166 0.9×	77	2.3k
Marie-Christine Étienne-Grimaldi France	27	508 0.4×	1.3k 1.3×	722 0.9×	343 1.5×	242 1.3×	82	1.9k
Zhenfan Yang China	19	1.2k 1.0×	1.1k 1.0×	549 0.7×	308 1.3×	108 0.6×	39	1.8k
Lone H. Ottesen United States	18	698 0.6×	618 0.6×	646 0.8×	214 0.9×	164 0.9×	56	1.4k
Dana T. Aftab United States	20	574 0.5×	882 0.9×	803 1.0×	417 1.8×	173 0.9×	45	1.8k

Countries citing papers authored by Weiwei Tan

Since Specialization

Citations

This map shows the geographic impact of Weiwei Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Tan more than expected).

Fields of papers citing papers by Weiwei Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiwei Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Tan. The network helps show where Weiwei Tan may publish in the future.

Co-authorship network of co-authors of Weiwei Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Weiwei Tan. A scholar is included among the top collaborators of Weiwei Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiwei Tan. Weiwei Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Derek Z., et al.. (2025). Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. British Journal of Clinical Pharmacology. 91(12). 3501–3510. 1 indexed citations

Guo, Qiang, et al.. (2025). DeformFlowNet: A deformable transformer with optical flow constraint for interventricular septum segmentation in echocardiography videos. Biomedical Signal Processing and Control. 108. 107952–107952.

Hamilton, Erika, Rinath Jeselsohn, Sara A. Hurvitz, et al.. (2024). Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort. Cancer Research. 84(9_Supplement). PS15–3. 2 indexed citations

Hamilton, E.P., Nicholas P. McAndrew, Melinda L. Telli, et al.. (2024). 218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results. ESMO Open. 9. 103240–103240. 7 indexed citations

Tan, Weiwei, et al.. (2024). Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib. Pharmaceutics. 16(1). 118–118.

Pu, Xingxiang, Juan Li, Bo Zhang, et al.. (2024). Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncology. 20(37). 2971–2982. 2 indexed citations

Telli, Melinda L., Wei Mo, Amita Patnaik, et al.. (2024). 264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 9. 103285–103285. 3 indexed citations

Hamilton, Erika, Hyo S. Han, Anne F. Schott, et al.. (2023). 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial. Annals of Oncology. 34. S344–S344. 12 indexed citations

Chang, Chee Tao, et al.. (2020). Bioequivalence and pharmacokinetic comparison of two fixed dose combination of Metformin/Glibenclamide formulations in healthy subjects under fed condition. PubMed. 75(3). 286–291. 3 indexed citations

10.

Tan, Weiwei, et al.. (2019). Tumor-to-tumor metastasis: a rare case of breast carcinoma metastasizing to a pheochromocytoma, and a literature review. Diagnostic Pathology. 14(1). 46–46. 7 indexed citations

11.

Tan, Weiwei, Nagdeep Giri, Susan Quinn, Keith D. Wilner, & Kourosh Parivar. (2019). Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer. Investigational New Drugs. 38(3). 874–884. 5 indexed citations

12.

Wang, Yongbin, Zhenfeng Jiang, Zhenxiang Li, et al.. (2019). Genome-wide identification and expression analysis of the VQ gene family in soybean ( Glycine max ). PeerJ. 7. e7509–e7509. 16 indexed citations

13.

He, Shenghua, et al.. (2018). Combining YESS and TESSYS techniques during percutaneous transforaminal endoscopic discectomy for multilevel lumbar disc herniation. Medicine. 97(28). e11240–e11240. 21 indexed citations

14.

Tan, Weiwei, et al.. (2017). Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways. OncoTargets and Therapy. Volume 10. 3467–3474. 44 indexed citations

15.

Wang, Erjian, Dana J. Nickens, Akintunde Bello, et al.. (2016). Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 22(23). 5722–5728. 20 indexed citations

16.

Ou, Sai‐Hong Ignatius, Ramaswamy Govindan, Keith D. Eaton, et al.. (2016). Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). 145–151. 40 indexed citations

17.

Patel, Sandip Pravin, Nathan A. Pennell, Suchita Pakkala, et al.. (2016). Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449. 2 indexed citations

18.

Li, Jun, Jie Ao, Kai Li, et al.. (2016). ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma. Cell Death and Disease. 7(10). e2428–e2428. 16 indexed citations

19.

Zhang, Yongqiang, Wei-Ya Wang, Jianxin Xue, et al.. (2016). MicroRNA Expression Profile on Solid Subtype of Invasive Lung Adenocarcinoma Reveals a Panel of Four miRNAs to Be Associated with Poor Prognosis in Chinese Patients. Journal of Cancer. 7(12). 1610–1620. 15 indexed citations

20.

Xu, Huiping, et al.. (2014). Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. The Journal of Clinical Pharmacology. 55(1). 104–113. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact